GU Cancers 2022 | ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, updates us on a post-hoc analysis evaluating overall survival (OS) in patients enrolled in ARCHES (NCT02677896) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis). The Phase III ARCHES trial investigated androgen deprivation therapy with enzalutamide versus ADT as monotherapy in patients with metastatic hormone-sensitive prostate cancer. The primary outcome was radiographic progression-free survival (rPFS) and secondary outcomes include overall survival and time to prostate-specific antigen (PSA) progression. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.